With the industry rapidly evolving, I'm convinced Biotech will be one of the strongest industries of the decade.
CRISPR technology, gene editing and genetic testing will help identify and cure diseases right at the core. AI will rapidly speed up drug development. And personalized medicine could result in a huge spike in quality of life and lifespan. And that’s just the beginning.
To help our readers identify clear-cut winners, we've pinpointed exciting biotech plays and found three strong-buys trading for less than, or close to $3 per share, but also boast huge long-term growth prospects, with upside profit potential of at least 200%. Plus, we've included details on our favorite CRISPR stock that's set to transform healthcare as we know it.
Here’s how the winners break down by category…
Best Value (Under $3):
Sintx Technologies is passionate about leveraging their expertise in the high-tech ceramics industry to create new, innovative opportunities in multiple sectors.
They have poured a tremendous amount of resources into the research and development of their hallmark silicon nitride material. They have leveraged the capability of this unique material to improve the quality of life for people all over the world—as well as expand into multiple industries.
Our pick: Sintx Technologies (NASDAQ:SINT)
Fastest Growing (Under $4):
Evoke Pharma, Inc is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US.
Our pick: Evoke Pharma Inc. (NASDAQ:EVOK)
Most Momentum (Under $3):
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders.
Our Pick: vTv Therapeutics (NYSE:VTVT)
$5 Biotech Pick: The Guardian: “New pill could spell the end of aging.”
Take a look at this picture:
On the surface, this pill looks just like any other…
But don't be fooled.
Inside is a revolutionary new technology that The Guardian reports could:
“spell the end of aging”
– The Guardian
And Scientific American says it could allow anyone that takes it to:
“stay young [forever]”
– Scientific American
This pill is set to completely change the lives of millions of Americans…
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams.
Featured Pick: “IMPERIUM:” The No. 1 Investment of the 2020s
Could this odd-looking machine really be the most transformative innovation in history?
Experts are screaming: “YES”!
Elon Musk calls it “amazing…”
A former Apple CEO says: “[It will] have a far bigger impact on humanity than the Internet.”
While a Harvard Ph.D. says it could “[surpass] the space, atomic, and electronic revolutions in its significance.”
It's a technology I call “Imperium.“
And it's about to spark the biggest investment mega trend in history … with one small Silicon Valley company at the center of it all.
To get all the details, click here now…
Breakthrough Strategy: Turn $1000 into $3900… In 27 Days… (Next Trade Incoming)
Trade ONE stock… ONCE per month… and walk away with massive gains?
Trading millionaire Jeff Clark says he's done it for years…
Helping over 170,000 folks discover how to turn petty cash into big returns – in bull OR bearish markets…
Check it out…
$61…
That's ALL it cost to get in on this trade…
“One Stock Retirement” | $61 Cost | 390% Gain | 27 Days
Jeff is now revealing a DEMONSTRATION to show you how you can get started trading… with less than $100!
Insider Alert: FDA Approval Could Send this Stock Soaring
Whenever the FDA approves a new drug… Timely investors could see 300-400% returns overnight…
CCXI returned 281% to investors in one day…
Relmada shot up 971% in 9 months…
Agile soared 305% in 5 months…
